Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical

Overview

Mental health and trauma impact a significant amount of adults in the United States, with 52.9 million adults experiencing a mental illness and 12 million adults experiencing PTSD. Unfortunately, treatment for mental illnesses is often ineffective, especially for trauma-based conditions. Psychedelics have emerged as a promising treatment for many mental illnesses, and two-thirds of physicians believe one psychedelic, psilocybin has therapeutic benefits.

Several neurological disorders, such as brain trauma, have shown promising results from psilocybin treatment. Mental illnesses such as major depression have also indicated encouraging results from psilocybin. Psychedelic compounds are generally considered non-addictive and suitable for the treatment of a wide variety of medical conditions. Companies that innovate safe and effective psychedelic medications are leading the charge towards a new era of mental health treatment.

Lobe Sciences (CSE:LOBE,OTCQB: LOBEF) is a Canadian-based life sciences company focused on researching and developing psychedelic medicines. The Company focuses on the clinical development of medicines to treat neurological disorders and brain trauma. Recently, Lobe Sciences announced the publication of a PCT patent application for its combination therapy for mTBI and PTSD. The Company’s mission is to identify and develop transformative new methods, medicines to improve brain health and provide new pathways for treating brain injuries and neurological disorders. Lobe Sciences is actively strengthening its balance sheet in Q1 2022.

Lobe Sciences undertakes the development of innovative medicines to treat mental health disorders and improve well-being while building a growing portfolio of intellectual property to protect our therapies. The company recently updated its scientific advisory board with experts in virtual reality, electronic engineering, and technologists to strengthen its pursuit of therapeutic VR devices.

Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. They are generally considered physiologically safe and do not lead to dependence or addiction. NAC is a dietary supplement derived from the amino acid L-cysteine. Taking NAC increases the level of glutathione, a potent antioxidant and anti-inflammatory molecule, in cells. Glutathione’s function is to protect cellular compounds such as DNA and prevent damage to them from reactive oxygen species and inflammatory cytokines. It is also used as an antidote for acetaminophen overdose.

Lobe Sciences’ vision is to administer the psilocybin and N-acetylcysteine (“NAC”) in doses that will be administered at home, in the emergency department or clinic. This will allow patients to remain with their primary physician and not be required to be confined in a clinic for eight or more hours to receive a hallucinatory dose of the psychedelic. The Company plans to…